Pfizer
-

Pfizer’s Covid-19 vaccine 95% effective in phase-3 study, says company
Scroll Staff
-

India working on strategy to procure Pfizer vaccine despite cold storage challenges, says Centre
Scroll Staff
-

Six questions (and answers) about Moderna and Pfizer’s vaccines showing promising results
Simon Kolstoe, The Conversation
-

Pfizer vaccine’s success is great news – but don’t expect life to ‘return to normal by spring’
Sarah Pitt, The Conversation
-

Coronavirus: US hopes to immunise 20 million in December, says vaccine programme head
Scroll Staff
-

Pfizer vaccine’s -70° Celsius storage requirement will be a challenge for India, says AIIMS director
Scroll Staff
-

We know Pfizer’s Covid vaccine works. But how well it works is still unknown
Anne Moore, The Conversation
-

Covid-19: ‘Government should work out logistics to make Pfizer vaccine available,’ says Rahul Gandhi
Scroll Staff
-

Sensex, Nifty close at record highs again as market sentiment turns positive over Pfizer vaccine
Scroll Staff
-

Coronavirus: 'Third spike in Delhi resulting in more cases than before,' says ICMR
Scroll Staff
-

Interview: Why Pfizer’s Covid-19 vaccine will be expensive and difficult to deliver in India
Smitha Nair
-

The big news: Pfizer says its coronavirus vaccine is over 90% effective, and nine other top stories
Scroll Staff
-

‘One step closer to ending pandemic’: Pfizer says its Covid-19 vaccine 90% effective in latest trial
Scroll Staff
-

Coronavirus: Pfizer says it could deliver 40 million doses of vaccine to US this year
Scroll Staff
-

Coronavirus: Vaccine makers Moderna and Pfizer reveal trial blueprint amid calls for transparency
Scroll Staff
-

Covid-19: US companies Moderna, Pfizer launch late-stage trials of vaccines
Scroll Staff
-

Pfizer has got a pneumonia vaccine patent. Will this hurt India’s immunisation programme?
Menaka Rao
-
The big news: Modi hails Supreme Court’s triple talaq verdict as historic, and 9 other top stories
Scroll Staff
-

Amid opposition, India gives Pfizer the patent to exclusively sell vital pneumonia vaccine
Scroll Staff
-

The business wrap: RBI keeps interest rate unchanged at 6.25%, and six other top stories
Scroll Staff